1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19
on Global Hematologic Malignancies Testing Market
5. Voice of Customer
6. Clinical Trial
Analysis
7.
Global Hematologic Malignancies Testing Market Outlook
7.1. Market Size &
Forecast
7.1.1. By Value
7.2. Market Share &
Forecast
7.2.1. By Component (Kits v/s Services)
7.2.1.1.
By Kits (Gene Panels, Molecular
Clonality Testing, Translocation Testing, Mutation Testing, Others)
7.2.2. By Technique (Next-Generation Sequencing (NGS),
Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH),
Immunohistochemistry (IHC), Others)
7.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple
Myeloma, Myeloproliferative Neoplasms, Others)
7.2.4. By End User (Hospitals & Clinics, Diagnostic
Laboratories, Academic & Research Institutions, Others)
7.2.5. By Company (2021)
7.2.6. By Region
7.3. Market Map
8.
North America Hematologic Malignancies Testing Market Outlook
8.1. Market Size &
Forecast
8.1.1. By Value
8.2. Market Share &
Forecast
8.2.1. By Component (Kits v/s Services)
8.2.1.1.
By Kits (Gene Panels,
Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
8.2.2. By Technique (Next-Generation Sequencing (NGS),
Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH),
Immunohistochemistry (IHC), Others)
8.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple
Myeloma, Myeloproliferative Neoplasms, Others)
8.2.4. By End User (Hospitals & Clinics, Diagnostic
Laboratories, Academic & Research Institutions, Others)
8.2.5. By Country
8.3. North America:
Country Analysis
8.3.1. United States Hematologic
Malignancies Testing Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Component
8.3.1.2.2.
By Technique
8.3.1.2.3.
By Therapeutic Indication
8.3.1.2.4.
By End User
8.3.2. Canada Hematologic
Malignancies Testing Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Component
8.3.2.2.2.
By Technique
8.3.2.2.3.
By Therapeutic Indication
8.3.2.2.4.
By End User
8.3.3. Mexico Hematologic
Malignancies Testing Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Component
8.3.3.2.2.
By Technique
8.3.3.2.3.
By Therapeutic Indication
8.3.3.2.4.
By End User
9.
Europe Hematologic Malignancies Testing Market Outlook
9.1. Market Size &
Forecast
9.1.1. By Value
9.2. Market Share &
Forecast
9.2.1. By Component (Kits v/s Services)
9.2.1.1.
By Kits (Gene Panels,
Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
9.2.2. By Technique (Next-Generation Sequencing (NGS),
Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH),
Immunohistochemistry (IHC), Others)
9.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple
Myeloma, Myeloproliferative Neoplasms, Others)
9.2.4. By End User (Hospitals & Clinics, Diagnostic
Laboratories, Academic & Research Institutions, Others)
9.2.5. By Country
9.3. Europe: Country
Analysis
9.3.1. France Hematologic
Malignancies Testing Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Component
9.3.1.2.2.
By Technique
9.3.1.2.3.
By Therapeutic Indication
9.3.1.2.4.
By End User
9.3.2. Germany Hematologic
Malignancies Testing Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Component
9.3.2.2.2.
By Technique
9.3.2.2.3.
By Therapeutic Indication
9.3.2.2.4.
By End User
9.3.3. United Kingdom Hematologic
Malignancies Testing Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Component
9.3.3.2.2.
By Technique
9.3.3.2.3.
By Therapeutic Indication
9.3.3.2.4.
By End User
9.3.4. Italy Hematologic
Malignancies Testing Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Component
9.3.4.2.2.
By Technique
9.3.4.2.3.
By Therapeutic Indication
9.3.4.2.4.
By End User
9.3.5. Spain Hematologic
Malignancies Testing Market Outlook
9.3.5.1.
Market Size & Forecast
9.3.5.1.1.
By Value
9.3.5.2.
Market Share & Forecast
9.3.5.2.1.
By Component
9.3.5.2.2.
By Technique
9.3.5.2.3.
By Therapeutic Indication
9.3.5.2.4.
By End User
10.
Asia-Pacific Hematologic Malignancies Testing Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Component (Kits v/s Services)
10.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing,
Translocation Testing, Mutation Testing, Others)
10.2.2. By Technique (Next-Generation Sequencing (NGS),
Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH),
Immunohistochemistry (IHC), Others)
10.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple
Myeloma, Myeloproliferative Neoplasms, Others)
10.2.4. By End User (Hospitals & Clinics, Diagnostic
Laboratories, Academic & Research Institutions, Others)
10.2.5. By Country
10.3.
Asia-Pacific: Country Analysis
10.3.1. China Hematologic
Malignancies Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Component
10.3.1.2.2.
By Technique
10.3.1.2.3.
By Therapeutic Indication
10.3.1.2.4.
By End User
10.3.2. India Hematologic
Malignancies Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Component
10.3.2.2.2.
By Technique
10.3.2.2.3.
By Therapeutic Indication
10.3.2.2.4.
By End User
10.3.3. Japan Hematologic
Malignancies Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Component
10.3.3.2.2.
By Technique
10.3.3.2.3.
By Therapeutic Indication
10.3.3.2.4.
By End User
10.3.4. South Korea Hematologic
Malignancies Testing Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1.
By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1.
By Component
10.3.4.2.2.
By Technique
10.3.4.2.3.
By Therapeutic Indication
10.3.4.2.4.
By End User
10.3.5. Australia Hematologic
Malignancies Testing Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1.
By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1.
By Component
10.3.5.2.2.
By Technique
10.3.5.2.3.
By Therapeutic Indication
10.3.5.2.4.
By End User
11.
South America Hematologic Malignancies Testing Market Outlook
11.1.
Market Size & Forecast
11.1.1. By Value
11.2.
Market Share & Forecast
11.2.1. By Component (Kits v/s Services)
11.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing,
Translocation Testing, Mutation Testing, Others)
11.2.2. By Technique (Next-Generation Sequencing (NGS),
Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH),
Immunohistochemistry (IHC), Others)
11.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple
Myeloma, Myeloproliferative Neoplasms, Others)
11.2.4. By End User (Hospitals & Clinics, Diagnostic
Laboratories, Academic & Research Institutions, Others)
11.2.5. By Country
11.3.
South America: Country Analysis
11.3.1. Brazil Hematologic
Malignancies Testing Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1.
By Component
11.3.1.2.2.
By Technique
11.3.1.2.3.
By Therapeutic Indication
11.3.1.2.4.
By End User
11.3.2. Argentina Hematologic
Malignancies Testing Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1.
By Component
11.3.2.2.2.
By Technique
11.3.2.2.3.
By Therapeutic Indication
11.3.2.2.4.
By End User
11.3.3. Colombia Hematologic
Malignancies Testing Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1.
By Component
11.3.3.2.2.
By Technique
11.3.3.2.3.
By Therapeutic Indication
11.3.3.2.4.
By End User
12.
Middle East and Africa Hematologic Malignancies Testing Market Outlook
12.1.
Market Size & Forecast
12.1.1. By Value
12.2.
Market Share & Forecast
12.2.1. By Component (Kits v/s Services)
12.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing,
Translocation Testing, Mutation Testing, Others)
12.2.2. By Technique (Next-Generation Sequencing (NGS),
Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH),
Immunohistochemistry (IHC), Others)
12.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple
Myeloma, Myeloproliferative Neoplasms, Others)
12.2.4. By End User (Hospitals & Clinics, Diagnostic
Laboratories, Academic & Research Institutions, Others)
12.2.5. By Country
12.3.
MEA: Country Analysis
12.3.1. South Africa Hematologic
Malignancies Testing Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1.
By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1.
By Component
12.3.1.2.2.
By Technique
12.3.1.2.3.
By Therapeutic Indication
12.3.1.2.4.
By End User
12.3.2. Saudi Arabia Hematologic
Malignancies Testing Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1.
By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1.
By Component
12.3.2.2.2.
By Technique
12.3.2.2.3.
By Therapeutic Indication
12.3.2.2.4.
By End User
12.3.3. UAE Hematologic
Malignancies Testing Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1.
By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1.
By Component
12.3.3.2.2.
By Technique
12.3.3.2.3.
By Therapeutic Indication
12.3.3.2.4.
By End User
12.3.4. Turkey Hematologic
Malignancies Testing Market Outlook
12.3.4.1. Market Size & Forecast
12.3.4.1.1.
By Value
12.3.4.2. Market Share & Forecast
12.3.4.2.1.
By Component
12.3.4.2.2.
By Technique
12.3.4.2.3.
By Therapeutic Indication
12.3.4.2.4.
By End User
12.3.5. Egypt Hematologic
Malignancies Testing Market Outlook
12.3.5.1. Market Size & Forecast
12.3.5.1.1.
By Value
12.3.5.2. Market Share & Forecast
12.3.5.2.1.
By Component
12.3.5.2.2.
By Technique
12.3.5.2.3.
By Therapeutic Indication
12.3.5.2.4.
By End User
13. Market Dynamics
13.1.
Drivers
13.2.
Challenges
14. Market Trends &
Developments
15. Competitive
Landscape
15.1.
Abbott Laboratories, Inc.
15.2.
Asuragen Inc.
15.3.
Bio-Rad Laboratories, Inc.
15.4.
Adaptive Biotechnologies Corporation
15.5.
F.Hoffmann-La-Roche AG
15.6.
Illumina, Inc.
15.7.
ICON plc.
15.8.
Invitae Corporation
15.9.
Laboratory Corporation of America Holdings
15.10.
Invivoscribe, Inc.
16. Strategic Recommendations